Kröger, Nicolaus

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 179

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT

Sarkar, S., Scherwath, A., Schirmer, L., Schulz-Kindermann, F., Neumann, K., Kruse, M., Dinkel, A., Kunze, S., Balck, F., Kröger, N., et al. (2014) · Bone Marrow Transplantation

Cancer survivorship and careChildhood Cancer Survivors' Quality of Life

Cited by 102

Stability and Priority of Symptoms and Symptom Clusters Among Allogeneic HSCT Patients Within a 5-Year Longitudinal Study

Esser, P., Kuba, K., Scherwath, A., Johansen, C., Schwinn, A., Schirmer, L., Schulz-Kindermann, F., Kruse, M., Koch, U., Zander, A. R., et al. (2017) · Journal of Pain and Symptom Management

Cancer survivorship and careHematopoietic Stem Cell Transplantation

Cited by 31

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML

Niederwieser, C., Morozova, E., Zubarovskaya, L., Zabelina, T., Klyuchnikov, E., Janson, D., Wolschke, C., Christopeit, M., Ayuk, F., Moiseev, I., et al. (2021) · Bone Marrow Transplantation

Hematopoietic Stem Cell TransplantationChronic Myeloid Leukemia Treatments

Cited by 24

Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

Ortí, G., Gras, L., Koster, L., Kulagin, A., Byrne, J., Apperley, J. F., Halaburda, K., Blau, I. W., Clark, A., Kröger, N., et al. (2024) · Transplantation and Cellular Therapy

Hematopoietic Stem Cell TransplantationRenal Transplantation Outcomes and Treatments

Cited by 9